Skip to main content

Table 2 Baseline WPAI scores: RAJ4

From: Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

WPAI domaina Placebo (N=170) Peficitinib 100 mg (N=174) Peficitinib 150 mg (N=174) Peficitinib 100 mg + 150 mg (N=348) p valueb
Absenteeismc
n 103 82 101 183 0.180
 Mean (SD) 9.18 (22.43) 4.75 (11.04) 5.89 (14.78) 5.38 (13.21)
Presenteeismc
n 99 83 101 184 0.994
 Mean (SD) 43.43 (26.15) 43.01 (30.71) 43.37 (28.05) 43.21 (29.20)
Loss of work productivityc
n 99 82 101 183 0.962
 Mean (SD) 45.28 (27.03) 44.37 (30.96) 45.53 (29.13) 45.01 (29.88)
Daily activity impairment
n 169 173 173 346 0.471
 Mean (SD) 52.60 (29.18) 48.84 (29.33) 50.69 (26.36) 49.77 (27.86)
  1. SD Standard deviation, WPAI Work Productivity and Activity Impairment
  2. aHigher WPAI scores indicate greater work/activity impairment, expressed as percentage
  3. bp values calculated using analysis of covariance, with no adjustment made for multiplicity
  4. cOnly “full-time paid workers” and “part-time paid workers” were included (not “homemakers”)